Nalefski E A, Rao A
Program in Cell and Development Biology, Harvard Medical School, Boston, MA 02115.
J Immunol. 1993 May 1;150(9):3806-16.
The hapten- and carrier-specific T lymphocyte clone D5 and a T hybridoma (D5h) derived from D5 cells recognize several different protein Ag conjugated with p-azobenzenearsonate (arsonate) presented by the class II MHC protein I-Ad. We show here that the ligand recognized by the D5 TCR is a complex of a haptenated peptide bound to I-Ad. We have identified a peptide fragment generated by enzymatic cleavage of arsonate-conjugated OVA (Ars-OVA), which stimulates D5 cells when presented by I-Ad-bearing APC. A synthetic peptide corresponding to this fragment, OVA(36-50), forms a ligand for D5h cells when it is conjugated with arsonate and presented by cells bearing I-Ad. Paraformaldehyde-fixed, I-Ad-bearing cells present Ars-OVA(36-50), or the longer stimulatory peptide Ars-OVA(33-49), to D5h cells, demonstrating that haptenated synthetic peptides can substitute for naturally processed antigenic peptides. The peptide Ars-OVA(33-49) binds to the major peptide-binding site of I-Ad because it competitively inhibited presentation of the peptide OVA(323-339), previously demonstrated to bind to I-Ad directly in vitro, to the OVA/I-Ad-specific T cell hybridoma 3DO-54.8. The unconjugated OVA(33-49) peptide failed to inhibit the presentation of OVA(323-339), demonstrating that the hapten facilities binding of the peptide to I-Ad. Conversely, the peptide OVA(323-339) competitively inhibited the presentation of Ars-OVA(33-49) to D5h cells, indicating that the two peptides Ars-OVA(33-49) and OVA(323-339) bind to overlapping sites on I-Ad. Amino acid substitutions introduced into the beta 1 domain of I-Ad that affected recognition of OVA(323-339) by 3DO-54.8 cells also affected recognition of Ars-OVA(33-50) by D5h cells, demonstrating that similar regions on I-Ad are required for TCR recognition of conventional as well as haptenated peptides. These results represent the first demonstration that the ligand recognized by a hapten- and carrier-specific T cell clone restricted to an MHC class II protein is a haptenated peptide Ag bound to the MHC molecule.
半抗原和载体特异性T淋巴细胞克隆D5以及源自D5细胞的T杂交瘤(D5h)可识别与对氨基苯砷酸(砷酸)偶联的几种不同蛋白质抗原,这些抗原由II类MHC蛋白I-Ad呈递。我们在此表明,D5 TCR识别的配体是与I-Ad结合的半抗原化肽复合物。我们鉴定出了一种由砷酸偶联的卵清蛋白(Ars-OVA)经酶切产生的肽片段,当由携带I-Ad的抗原呈递细胞(APC)呈递时,该片段可刺激D5细胞。与该片段对应的合成肽OVA(36 - 50),在与砷酸偶联并由携带I-Ad的细胞呈递时,可形成D5h细胞的配体。用多聚甲醛固定的、携带I-Ad的细胞将Ars-OVA(36 - 50)或更长的刺激肽Ars-OVA(33 - 49)呈递给D5h细胞,这表明半抗原化的合成肽可替代天然加工的抗原肽。肽Ars-OVA(33 - 49)与I-Ad的主要肽结合位点结合,因为它竞争性抑制了肽OVA(323 - 339)(先前已证明其在体外可直接与I-Ad结合)向OVA/I-Ad特异性T细胞杂交瘤3DO - 54.8的呈递。未偶联的OVA(33 - 49)肽未能抑制OVA(323 - 339)的呈递,这表明半抗原促进了该肽与I-Ad的结合。相反,肽OVA(323 - 339)竞争性抑制了Ars-OVA(33 - 49)向D5h细胞的呈递,这表明Ars-OVA(33 - 49)和OVA(323 - 339)这两种肽在I-Ad上结合重叠位点。引入到I-Ad的β1结构域中的氨基酸取代影响了3DO - 54.8细胞对OVA(323 - 339)的识别,也影响了D5h细胞对Ars-OVA(33 - 50)的识别,这表明I-Ad上的相似区域对于TCR识别常规肽以及半抗原化肽都是必需的。这些结果首次证明,受限于II类MHC蛋白的半抗原和载体特异性T细胞克隆识别的配体是与MHC分子结合的半抗原化肽抗原。